Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 24Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

venetoclax 190Cyclophosphamide 123Azacitidine 112Cytarabine 108fludarabine 91Specimen Handling 74Biopsy 53Daunorubicin 42Methotrexate 41Dexamethasone 38Rituximab 34blinatumomab 32Vincristine 32Decitabine 31fludarabine phosphate 30Injections 28Granulocyte Colony-Stimulating Factor 28Whole-Body Irradiation 26Magnetic Resonance Spectroscopy 26obinutuzumab 25Idarubicin 25acalabrutinib 23Prednisone 23Mycophenolic Acid 23Melphalan 21Busulfan 21gilteritinib 19Mercaptopurine 19Doxorubicin 19ibrutinib 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × orelabrutinib × Other hematologic neoplasm × Clear all
NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
79 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06378138 2025-11-21

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2/3 Recruiting
226 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡